Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
UBS
Accenture
Farmers Insurance
Daiichi Sankyo
Harvard Business School
Moodys
US Department of Justice
Healthtrust

Generated: July 22, 2018

DrugPatentWatch Database Preview

Trimipramine maleate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for trimipramine maleate and what is the scope of trimipramine maleate freedom to operate?

Trimipramine maleate
is the generic ingredient in two branded drugs marketed by Odyssey Pharms, Crossmedika Sa, Elite Labs Inc, and Usl Pharma, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for trimipramine maleate. Four suppliers are listed for this compound.
Summary for trimipramine maleate
Pharmacology for trimipramine maleate
Medical Subject Heading (MeSH) Categories for trimipramine maleate
Synonyms for trimipramine maleate
(-)-Trimipramine maleate
(+)-Trimipramine maleate
(2Z)-BUT-2-ENEDIOIC ACID; (3-{2-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,12,14-HEXAEN-2-YL}-2-METHYLPROPYL)DIMETHYLAMINE
(Z)-but-2-enedioic acid; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
(Z)-but-2-enedioic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
10,11-Dihydro-N,N,|A-trimethyl-5H-dibenz[b,f]azepine-5-propanamine (2Z)-2-butenedioate
138283-60-0
138283-61-1
2768AH
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethyl-propan-1-amine; maleic acid
5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine maleate (1:1)
521-78-8
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-, (2Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-, (Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-, (2Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-, (Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (2Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (Z)-2-butenedioate (1:1)
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, maleate (1:1)
739-71-9 (Parent)
AC1NQZV7
ACM521788
AKOS026750012
AN-10861
C14029
C20H26N2.C4H4O4
CAS-521-78-8
CCG-39308
CHEBI:35030
CHEMBL1200948
CS-4840
D02408
D28E1043W5
DSSTox_CID_25315
DSSTox_GSID_45315
DSSTox_RID_80796
DTXSID2045315
EINECS 208-318-3
EU-0101156
HMS1570B13
HMS1922G07
HMS2092L08
HMS2097B13
HMS2233H17
HMS3263H13
HMS500E15
HY-B1213
I412286V22
LP01156
LS-173816
LS-60411
MFCD00082376
MLS001056765
MolPort-003-666-451
NCGC00016013-06
NCGC00016483-01
NCGC00094418-01
NCGC00094418-02
NCGC00094418-03
NCGC00094418-04
NCGC00094418-05
NCGC00261841-01
NSC-758386
NSC758386
Pharmakon1600-01503117
PL001324
Prestwick_1022
SCHEMBL41289
SMR000326720
SPECTRUM1503117
SR-01000076152
SR-01000076152-1
Surmontil (TN)
Surmontil maleate
T 3146
Tox21_110449
Tox21_110449_1
Tox21_501156
Trimeprimine maleate
Trimeprimine monomaleate
Trimipramine (maleate)
Trimipramine acid maleate
Trimipramine hydrogen maleate
Trimipramine Maleate (1:1)
Trimipramine maleate (JAN/USAN)
Trimipramine maleate [USAN:JAN]
Trimipramine maleate [USAN:USP:JAN]
Trimipramine Maleate 1.0 mg/ml in Methanol (as free base)
Trimipramine maleate salt
Trimipramine maleate, (-)-
Trimipramine maleate, (+)-
Trimipraminhydrogenmaleat
Trimipramini maleas
Trimipramium maleinicum
UNII-D28E1043W5
UNII-I412286V22

US Patents and Regulatory Information for trimipramine maleate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elite Labs Inc TRIMIPRAMINE MALEATE trimipramine maleate CAPSULE;ORAL 077361-002 Aug 2, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Odyssey Pharms SURMONTIL trimipramine maleate CAPSULE;ORAL 016792-003 Sep 15, 1982 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Odyssey Pharms SURMONTIL trimipramine maleate CAPSULE;ORAL 016792-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Usl Pharma TRIMIPRAMINE MALEATE trimipramine maleate CAPSULE;ORAL 071283-001 Dec 8, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Federal Trade Commission
Johnson and Johnson
Healthtrust
Accenture
Cipla
UBS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.